Media coverage about Leap Therapeutics (NASDAQ:LPTX) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.6688255877403 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Zacks Investment Research cut shares of Leap Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th.
Leap Therapeutics (NASDAQ:LPTX) traded up $0.11 on Tuesday, reaching $6.38. 39,200 shares of the company traded hands, compared to its average volume of 77,620. Leap Therapeutics has a 52 week low of $4.90 and a 52 week high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last posted its earnings results on Monday, November 13th. The company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.11). equities analysts predict that Leap Therapeutics will post -3.63 EPS for the current fiscal year.
In other Leap Therapeutics news, COO Augustine Lawlor acquired 1,057,769 shares of the stock in a transaction on Tuesday, November 14th. The stock was acquired at an average price of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 58.40% of the stock is owned by company insiders.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.